Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.
Clin Transl Oncol
; 12(7): 468-72, 2010 Jul.
Article
em En
| MEDLINE
| ID: mdl-20615823
ABSTRACT
Sarcomas are uncommon malignancies that represent more than 50 different tumor types. Surgery remains the mainstay of treating localised disease. Anthracycline and ifosfamide-based chemotherapy is an option for advanced disease; however, effective treatment of advanced soft tissue sarcoma remains a challenge. Advances in understanding the genetic nature of cancer have led to the development of new treatment options for sarcoma. Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor with antiangiogenic properties and promising activity in the treatment of GIST refractory to imatinib, however in either soft tissue sarcoma, experience with sunitinib is under development in different clinical trials. In this review we offer the experience with this small molecular target in non-GIST sarcomas.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pirróis
/
Sarcoma
/
Proteínas Tirosina Quinases
/
Inibidores de Proteínas Quinases
/
Indóis
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Revista:
Clin Transl Oncol
Ano de publicação:
2010
Tipo de documento:
Article
País de afiliação:
Espanha